Some hair loss in men is linked to weight loss drug use
· Medical Xpressedited by Gaby Clark, reviewed by Robert Egan
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Men already genetically at risk for the most common form of hair loss have a 7% added risk of losing their hair if they use drugs like Ozempic, Wegovy and Zepbound for type 2 diabetes and obesity, a new study shows.
Led by researchers at NYU Langone Health, the study focused on the GLP1R gene, which naturally increases the body's levels of glucagon-like peptide-1 (GLP-1) receptor proteins, and used it as an indicator of GLP-1 agonist activity. More GLP1R activity means there are more GLP-1 receptor proteins.
The researchers compared the presence of GLP1R genes with the presence of genes found in men with androgenetic alopecia, an inherited form of hair loss that follows a pattern along the top and front of the scalp. Male hair loss conditions are well studied, unlike hair loss in women, which is why the researchers could only analyze a causal link to hair loss in men.
From reported side effect to genetic link
Many GLP-1 users, both men and women, have reported thinning hair as a side effect, with researchers so far attributing the shedding to the rapid weight loss driven by the medications, which work to regulate blood sugar and suppress appetite. Often, GLP-1 users have found that hair growth resumes several months after their weight stabilizes. Until now, researchers had only suspected a genetic connection between GLP-1 use and hair loss.
Published online Sept. 3 in the Journal of Investigative Dermatology, the study showed that the GLP1R genes that naturally cause higher levels of GLP-1 receptor proteins are more likely to be present in men who have androgenetic alopecia. The researchers then adjusted their analysis to account for known risks of hair loss from hypertension, which is thought to reduce blood flow to the scalp and harm hair follicle growth. The 7% added risk remained the same.
Researchers also checked their risk analysis against other potential drivers of hair loss, including insulin resistance (a cause of type 2 diabetes) and lowered testosterone levels. Still, the increased risk of hair loss from GLP-1 use remained at 7%.
Screening and prevention possibilities
Because the study involved genes active in both GLP-1 users and men with hair loss, any overlapping risk, the researchers noted, suggests that the two are biologically linked.
"Our study provides the first genetic link between GLP-1 use and an increased risk of male-pattern hair loss from androgenetic alopecia, an association long suspected but until now not shown scientifically," said study senior investigator Lynn Petukhova, Ph.D., an assistant professor in the Ronald O. Perelman Department of Dermatology and the Department of Population Health at NYU Grossman School of Medicine.
"Our findings suggest that, if future experiments prove successful, some men, and possibly women too, could be screened and benchmarked for their risk of hair loss before being prescribed GLP-1 medications," said Petukhova. "We could also envision these findings leading to some GLP-1 users being prescribed combination treatments to prevent hair loss, such as minoxidil or some other drug."
Petukhova said further research is needed to understand the biological mechanisms that cause GLP-1 use to weaken hair follicle growth. She also has plans to investigate whether the links seen in men apply to women.
Who was studied and why it stands out
For the study, researchers accessed large, publicly available genetic databases, including the eQTLGen database of 31,684 mostly white men and women and the Complex Traits Genetics group database of 205,327 mostly white men.
Androgenetic alopecia is estimated to affect half of white American males older than 50 and almost the same number of white American females older than 50, predominantly those who are postmenopausal.
An estimated 12% of Americans have used GLP-1 drugs for no other reason than weight loss, including one-fifth of women ages 50 to 64, according to surveys. Since the first GLP-1 drug, Ozempic, was approved by the Food and Drug Administration in 2020, prescriptions for the medication have more than tripled.
Publication details
A causal effect of increased GLP1R expression on Male Pattern Hair Loss is suggested by Two-Sample Mendelian Randomization, Journal of Investigative Dermatology (2026). DOI: 10.1016/j.jid.2026.07.024
Journal information: Journal of Investigative Dermatology
Key medical concepts
Androgenetic alopeciaGLP1R Gene
Clinical categories
DermatologySkin & Hair careEndocrinologyWeight managementClinical pharmacologyMen's health Provided by NYU Langone Health Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Some hair loss in men is linked to weight loss drug use (2026, September 3) retrieved 3 September 2026 from https://medicalxpress.com/news/2026-09-hair-loss-men-linked-weight.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.